Cahill Financial Advisors’s Gilead Sciences GILD Stock Holding History

Cahill Financial Advisors’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$447K	Sell	3,540 -177	-5%	-$23.3K	0.04%	196
2026 Q1	$518K	Buy	3,717 +38	+1%	+$5.32K	0.06%	174
2025 Q4	$452K	Sell	3,679 -22	-0.6%	-$2.67K	0.05%	185
2025 Q3	$411K	Buy	3,701 +73	+2%	+$8.3K	0.05%	194
2025 Q2	$402K	Buy	3,628 +3	+0.1%	+$319	0.05%	195
2025 Q1	$406K	Buy	3,625 +3	+0.1%	+$310	0.06%	189
2024 Q4	$335K	Buy	+3,622	New	+$326K	0.05%	201
2021 Q4	–	Sell	-860	Closed	-$60K	–	431
2021 Q3	$60K	Buy	+860	New	+$60.4K	0.01%	318

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Cahill Financial Advisors's GILD Position: Q2 2026 in Review

Cahill Financial Advisors reduced its Gilead Sciences (GILD) stake by 4.8% in Q2 2026, selling an estimated $23.3K and leaving 3,540 shares worth $447K. The position accounts for 0.04% of the portfolio, ranked #196.

Cahill Financial Advisors first reported a position in GILD in Q3 2021 and has held it in 8 quarters since. The position peaked at $518K in Q1 2026. 2,290 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

Cahill Financial Advisors held 3,540 shares of Gilead Sciences worth $447K as of Q2 2026.
Cahill Financial Advisors sold 177 Gilead Sciences shares in Q2 2026, an estimated $23.3K.
Gilead Sciences made up 0.04% of Cahill Financial Advisors's portfolio in Q2 2026, its #196 holding.
Cahill Financial Advisors first reported a position in Gilead Sciences in Q3 2021 and has held it in 8 quarters since.
Cahill Financial Advisors's Gilead Sciences position peaked at $518K in Q1 2026.
2,290 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Cahill Financial Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.